Skip to main content
. 2017 Aug 14;8(50):87317–87328. doi: 10.18632/oncotarget.20264

Figure 3.

Figure 3

The overall survival (OS, a) and progression-free survival (PFS, b) according to the level of PD-1 expression among subgroup of patients who did not receive upfront autologous stem-cell transplantation (ASCT).